APA (7th ed.) Citation

Xu, Y., Qi, Y., Lu, Z., Tan, Y., Chen, D., & Luo, H. Navigating precision: The crucial role of next-generation sequencing recurrence risk assessment in tailoring adjuvant therapy for hormone receptor-positive, human epidermal growth factor Receptor2-negative early breast cancer. Taylor & Francis Group.

Chicago Style (17th ed.) Citation

Xu, Ying, Yingxue Qi, Zhongyu Lu, Yuan Tan, Dongsheng Chen, and Haijun Luo. Navigating Precision: The Crucial Role of Next-generation Sequencing Recurrence Risk Assessment in Tailoring Adjuvant Therapy for Hormone Receptor-positive, Human Epidermal Growth Factor Receptor2-negative Early Breast Cancer. Taylor & Francis Group.

MLA (9th ed.) Citation

Xu, Ying, et al. Navigating Precision: The Crucial Role of Next-generation Sequencing Recurrence Risk Assessment in Tailoring Adjuvant Therapy for Hormone Receptor-positive, Human Epidermal Growth Factor Receptor2-negative Early Breast Cancer. Taylor & Francis Group.